Latest News

Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story

02/05/2023
Resolution Appoints Liver Disease Expert, Dr Clifford A. Brass, as Chief Medical Officer

London, 2 May 2023 – Resolution Therapeutics announces the appointment of Dr. Clifford A. Brass, as Chief Medical Officer.

30/03/2023
Resolution Expands its CMC Capabilities with Key Hires

London, 30 March 2023 - Resolution Therapeutics announces the appointment of key senior CMC hires in regulatory, quality, process development, analytical development and project management.

09/11/2022
Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors

London, 9 November 2022 - Resolution announced today the appointment of Lisa Bright as Chairman of its Board of Directors

07/11/2022
Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for iPSC-derived macrophage cell therapies

London, UK and Toronto, Canada, 7 November, 2022 – Resolution Therapeutics and CCRM announce the signing of a collaboration in iPSC-derived macrophage cell therapies.

20/07/2022
Resolution Therapeutics Appoints Bill Symonds to its Board of Directors

London, 20 April 2021 – Resolution Therapeutics announces the appointment of Bill Symonds as a Non-Executive Director of the Company.

30/06/2022
Resolution Therapeutics Appoints Dr Amol Ketkar as Chief Development Officer

London, 30 June, 2022 – Resolution Therapeutics announces the appointment of Dr. Amol Ketkar, as Chief Development Officer.

05/04/2022
Resolution Therapeutics and panCELLa Inc announce a Research Evaluation and Option Agreement to develop iPSC-derived macrophage cell therapy for inflammatory organ disease

London and Toronto, 5 April 2022 - Resolution Therapeutics partners with panCELLa to develop iPSC-derived macrophage cell therapy for inflammatory organ disease.

05/04/2022
Resolution Therapeutics Announces a £10m Extended Series A Financing from Syncona Ltd

London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to broaden its research pipeline into allogeneic macrophages for the treatment of liver disease.

17/02/2022
Resolution Therapeutics Strengthens its Team with Two New Appointments

London, 17 February 2022 – Resolution Therapeutics announces the strengthening of its senior management team with the appointments of Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance.